Lu Hongbo 4

4 · Zenas BioPharma, Inc. · Filed Feb 13, 2026

AI-generated summary of this filing

Updated Feb 13, 2026

Zenas BioPharma (ZBIO) Director Lu Hongbo Buys 25,985 Shares

What Happened

Director Lu Hongbo reported an open-market purchase of 25,985 shares of Zenas BioPharma (ZBIO) on 2026-02-11 at $22.50 per share, for a total reported value of $584,663. This was a purchase (transaction code P), which is generally viewed as a more informative insider action than routine sales.

Key Details

Transaction date: 2026-02-11; Price: $22.50 per share; Shares acquired: 25,985; Total value: $584,663.
Transaction type: P = Purchase (open market/private purchase reported as such).
Shares owned after transaction: Not stated in the filing.
Filing: Report filed 2026-02-13 — within the two-business-day Form 4 reporting window (timely).
Footnotes of note:
- F1: The securities are directly owned by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be indirectly beneficially owned by NEXTBio-related entities and Lu Hongbo in his capacities with those entities.
- F2: The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.

Context

The purchase appears to be through NEXTBio-affiliated vehicles (per F1), so this filing reflects indirect beneficial ownership via those funds rather than necessarily a personal, individual buy-and-hold. F2 clarifies the reporter disclaims beneficial ownership beyond pecuniary interest. No options, grants, gifts, or tax-withholding events were reported in this filing.

Form 4

Period: 2026-02-11

Director

Transactions

Purchase
Common Stock
[F1][F2]
2026-02-11$22.50/sh+25,985$584,663→ 347,968 total(indirect: See footnote)

Footnotes (2)

[F1]The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio EverGreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC.
[F2]The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Signature

Hongbo Lu, By: /s/ Hongbo Lu|2026-02-13

1 file